ライフサイエンスコーパス: tachyplesin

1 in potency of 2-10-fold compared to that of tachyplesin.

2 nt for the membrane-disruptive activities of tachyplesins.

3 was examined in two peptide series based on tachyplesin, a known beta-stranded antimicrobial peptide

4 4 dendrimer are comparable to protegrins and tachyplesins, a family of potent antimicrobials containi

5 Finally, the combination of tachyplesin and human serum markedly inhibited the proli

6 y to identify a protein that interacted with tachyplesin and isolated a sequence corresponding to the

7 Treatment of cells with tachyplesin and serum increased in membrane permeability

8 en together, these observations suggest that tachyplesin binds to both hyaluronan on the cell surface

9 ed the charge and hydrophobic amino acids of tachyplesin, but contained zero to four covalent constra

10 e charges resembling those in protegrins and tachyplesins, but were less cytotoxic.

11 nt constraints, included a cyclic tricystine tachyplesin (ccTP 1).

12 In this study, a synthetic tachyplesin conjugated to the integrin homing domain RGD

13 Cyclic tachyplesins consisting of 14 and 18 amino acids are con

14 ting showed that treatment of cells with RGD-tachyplesin could activate caspase 9, caspase 8, and cas

15 O-PRO-1, and FITC-dextran indicated that RGD-tachyplesin could induce apoptosis in both tumor and end

16 The in vivo studies indicated that the RGD-tachyplesin could inhibit the growth of tumors on the ch

17 e disulfide-stabilized antimicrobial peptide tachyplesin I (TP) in lipid bilayers are determined by s

18 role of amphipathicity using an analogue of tachyplesin I (TP-I), CDT (KWFRVYRGIYRRR-NH(2)), in whic

19 an NMR structural investigation of wild-type tachyplesin I and three linear derivatives (denoted TPY4

20 also determined the structures of wild-type tachyplesin I and TPY4 in the presence of dodecylphospho

21 elle and aqueous solution for both wild-type tachyplesin I and TPY4 reveals two requirements for high

22 cribe the chemical synthesis of a variant of tachyplesin I in which its two disulfide bonds are in a

23 Tachyplesin I is a 17-residue peptide isolated from the

24 Tachyplesin I is a cyclic beta-sheet antimicrobial pepti

25 The four cysteine residues in tachyplesin I play a structural role in imparting amphip

26 Our substrate is based on tachyplesin I, a 17-mer peptide that folds into a beta h

27 For a beta-sheet peptide tachyplesin I, which may be quite ordered at the solid/l

28 rization of the disulfide bonds in nonnative tachyplesin I.

29 Tachyplesin-I (TP-I) is a 17-residue beta-hairpin antimi

30 of resistance against certain AMPs, such as tachyplesin II and cecropin P1, is limited.

31 variants could be prevented by administering tachyplesin in combination with sertraline, a clinically

32 When TSU tumor cells were treated with tachyplesin in the presence of serum, activated C4b and

33 The in vitro results showed that RGD-tachyplesin inhibited the proliferation of both cultured

34 Tachyplesin is a small, cationic peptide that possesses

35 Tachyplesin is an antimicrobial peptide present in leuko

36 Tachyplesin seemed to activate the classic complement ca

37 eric cystine-stabilized beta-strand (CSbeta) tachyplesin (TP) in a panel of 10 test organisms.

38 chia coli and Pseudomonas aeruginosa survive tachyplesin treatment without acquiring genetic mutation

39 rophobic amino acid) found in protegrins and tachyplesins whereas the octapeptide R8 (RLYRKVYG) consi